Untch et al. [15] evaluated the efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2(HER2)-overexpressing breast cancer. This evidence concerns the gene ERBB2 and breast cancer.